Two monoclonal antibody treatments to slow Alzheimer’s disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years. It’s thought the drugs curb Alzheimer’s by reducing levels of toxic amyloid protein plaques in the brain. But what if another neurological effect could explain the benefit?…  read on >  read on >

Ozempic and Wegovy can prevent heart problems in overweight and obese people, particularly if they also suffer from kidney disease, a new clinical trial shows. The drugs’ active ingredient, semaglutide, reduced heart health risk by 20% in heavyset people who took it for more than three years, researchers reported Wednesday at the European Association for…  read on >  read on >

Less than half of people who’ve survived a stroke will go on to have a healthy, normal sleep pattern, new research shows. Normal sleep is defined as six to eight hours of shuteye nightly. However, a majority of the nearly 1,600 stroke survivors in the new study got either too much or too little sleep.…  read on >  read on >

People with diabetes are more prone to gum disease, due to the damage the chronic illness does to small blood vessels, a new study warns. Diabetics who suffer from other diseases caused by small blood vessel damage — diabetic retinopathy and neuropathy — are also at higher risk for gum disease, researchers found. People were 21%…  read on >  read on >

An analysis of where suicides are occurring in the United States shows that, tragically, location matters. People living in poorer areas with fewer resources are significantly more likely to fall victim to suicide versus those living in more affluent areas, new data from the U.S. Centers for Disease Control and Prevention shows. “Improving the conditions…  read on >  read on >